Physician profile
Corey E Henderson
NPI 1568834224
$2,256.60
in general payments reported to CMS, 2019-2025
24 companies · $683 in 2025
The $683 reported for 2025 was more than what 80% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $233 · 2023: $371 · 2024: $706 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $442.52 | 2023-2025 | |
| Abbvie INC. | $311.45 | 2021-2025 | |
| Madrigal Pharmaceuticals | $263.29 | 2024-2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $133.41 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $132.72 | 2021-2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $129.22 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $93.19 | 2023-2025 | Ocaliva |
| Genzyme Corporation | $80.60 | 2023-2025 | |
| Novo Nordisk INC | $74.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.19 | 2022-2023 | Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.75 | 2023-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $61.34 | 2023-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $56.89 | 2023-2025 | Stelara, Simponi Aria, Tremfya |
| Amgen INC. | $55.29 | 2021-2025 | |
| Evoke Pharma, INC. | $47.86 | 2023-2025 | Gimoti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.68 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.17 | 2022 | |
| Exact Sciences Corporation | $32.29 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $29.60 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $19.41 | 2024 | Bylvay |
| Merck Sharp & Dohme LLC | $16.56 | 2022 | |
| Glaxosmithkline, LLC. | $12.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.